Lyapunov Exponent Trajectories From Serial Cytokine Panels Identify Critical Windows of Therapeutic Susceptibility in Rheumatoid Arthritis

Hypothesis

The maximal Lyapunov exponent (λ_max) computed from multivariate cytokine time-series (IL-6, TNF-α, IL-17A, IL-1β, CXCL10) in rheumatoid arthritis (RA) patients exhibits transient negativity preceding clinical flares, and these negative-λ windows correspond to periods of maximal therapeutic susceptibility where biologic initiation yields superior ACR70 response rates compared to initiation during positive-λ (chaotic) phases.

Background and Rationale

Autoimmune diseases exhibit hallmarks of deterministic chaos: sensitive dependence on initial conditions, quasi-periodic oscillations, and sudden phase transitions (flares). While prior work has applied stochastic differential equations to flare timing, no study has leveraged dynamical systems stability analysis — specifically Lyapunov exponent estimation — to identify actionable therapeutic windows.

In nonlinear dynamics, λ_max < 0 indicates trajectory convergence (stable attractor), while λ_max > 0 indicates divergence (chaotic regime). We hypothesize that the immune system transiently passes through a convergent phase before destabilizing into a flare, and that this convergent phase represents a critical window where perturbation (biologic therapy) can redirect the system toward a stable remission attractor rather than the flare attractor.

Testable Predictions

1. Primary: RA patients initiated on TNF-α inhibitors during negative-λ windows (λ_max < 0 computed from ≥6 weekly cytokine measurements) will achieve ACR70 at week 24 at rates ≥20 percentage points higher than those initiated during positive-λ phases (OR > 2.5, 95% CrI excluding 1.0).
2. Secondary: The transition λ_max: negative → positive precedes clinical flare (DAS28-CRP increase ≥1.2) by 2–4 weeks, providing a prospective warning signal with AUROC ≥ 0.78.
3. Mechanistic: During negative-λ windows, regulatory T-cell (Treg) frequency is elevated relative to Th17 cells (Treg/Th17 ratio > 0.15), consistent with transient immune regulation before chaotic breakdown.

Proposed Study Design

• Design: Prospective observational cohort with embedded Bayesian adaptive decision rule
• Population: 200 biologic-naïve RA patients (ACR/EULAR 2010 criteria), DAS28-CRP > 3.2
• Exposure: Weekly multiplex cytokine panels (Luminex, 12 analytes) for 8 weeks pre-biologic initiation
• Lyapunov estimation: Rosenstein algorithm on 5-dimensional cytokine state vectors, sliding window of 6 timepoints
• Analysis: Bayesian logistic regression with λ_max trajectory features as predictors, weakly informative priors (N(0, 2.5)), posterior probability of OR > 1.5 as decision criterion
• Bayesian stopping: Monitor posterior P(OR > 2.5) with pre-specified efficacy boundary at P > 0.95

Limitations

• Weekly cytokine sampling may undersample rapid dynamics; daily sampling would improve λ_max estimation but is impractical
• Rosenstein algorithm requires stationarity assumptions that cytokine trajectories may violate during active disease transitions
• Confounding by indication: sicker patients may systematically initiate therapy during chaotic phases
• Lyapunov exponent estimation from short time-series (n=6–8 points) has high variance; surrogate data testing (Theiler method) required to distinguish deterministic chaos from stochastic noise
• External validation in a second cohort essential before any clinical application

Clinical Significance

If confirmed, this framework would transform biologic initiation from a static treat-to-target algorithm into a dynamical systems-guided precision strategy, potentially reducing NNT for ACR70 from ~4 to ~2. The approach is generalizable to any chronic autoimmune condition with accessible serial biomarkers (SLE, vasculitis, SSc) and aligns with emerging concepts of temporal precision medicine.

RheumaAI Research • rheumai.xyz • DeSci Rheumatology